Basic Anafranil Information

• INN (International Nonproprietary Name): Clomipramine
• Brand Names Available In Australia: Anafranil, Clopram, Clofranil
• ATC Code: N06AA04
• Forms & Dosages: Capsules and tablets commonly available in 10 mg (varies), 25 mg, 50 mg and 75 mg strengths for oral administration.
• Manufacturers In Australia: Not specified; global suppliers include Novartis (via Sandoz), Sun Pharma, Zydus, Torrent, Teva and Sanofi.
• Registration Status In Australia: Prescription-only medication (Rx) in all countries surveyed; check TGA listings for specific details.
• OTC / Rx Classification: Prescription-only medication (Rx)

Latest Research Highlights

Patients and clinicians often ask whether clomipramine still has a role after new SSRI data — recent literature shows it does for many treatment‑resistant cases.

Australian observational series between 2022 and 2025 and international randomised trials reaffirm clomipramine’s utility in moderate to severe obsessive–compulsive disorder where first‑line SSRIs fail to achieve remission.

Several international randomised placebo‑controlled trials from 2022–2024 reported superior symptom reduction measured by validated scales compared with placebo in refractory OCD cohorts.

Head‑to‑head comparisons with high‑dose SSRIs show mixed results, with many trials limited by older designs and small samples.

Safety updates over 2022–2025 emphasise the anticholinergic burden, QT‑interval prolongation risk and a lowered seizure threshold, prompting recommendations for cardiac and seizure‑risk screening before escalation.

TGA adverse‑event reporting mirrors wider pharmacovigilance, with more recorded anticholinergic and cardiovascular events in elderly, frail and polypharmacy settings.

Recent systematic reviews and meta‑analyses recommend clomipramine as second‑line monotherapy or as an augmentation option for refractory OCD and severe rumination not responding to SSRIs.

Gaps in the evidence include few contemporary Australian RCTs, limited pharmacogenomic data for Indigenous populations and sparse long‑term PBS outcome studies.

Clinical Effectiveness In Australia

Clinicians commonly ask how clomipramine performs in routine Australian practice compared with SSRIs — PBS dispensing and tertiary clinic reports provide the answer.

PBS dispensing data show lower overall use than SSRIs, but steady prescribing within specialist psychiatric clinics and tertiary services for refractory OCD.

Real‑world outcomes recorded in Australian services typically demonstrate substantial Yale‑Brown Obsessive Compulsive Scale (Y‑BOCS) reductions in patients who have failed two or more SSRIs or cognitive behavioural therapy.

These clinical improvements align with international guidelines that list clomipramine as a second‑line option for refractory OCD.

TGA adverse‑event surveillance in Australia specifically flags elderly patients and those with cardiac comorbidity for intensified monitoring.

Hospitals and specialist services often obtain baseline ECGs and repeat monitoring before escalating doses above 100 mg/day.

Outcome Measures (definitions):

• Y‑BOCS: Yale‑Brown Obsessive Compulsive Scale, measures OCD severity.
• CGI‑I: Clinical Global Impression – Improvement, rates overall clinical change.

Indications And Expanded Uses

Patients commonly want to know what anafranil is approved for and what it’s used off‑label for in Australia.

Regulatory approvals primarily cover obsessive–compulsive disorder; the FDA also explicitly approves clomipramine for OCD in adults and paediatric patients aged 10 and over.

Off‑label Australian uses include severe or melancholic depression, refractory panic disorder and augmentation strategies in treatment‑resistant cases, typically under specialist supervision.

Paediatric use is cautious and usually limited to OCD indications with specialist dosing guidance.

Specialist psychiatrists reserve clomipramine for patients who are intolerant of SSRIs, partial responders to SSRIs, or those with predominant compulsive rituals where tricyclic serotonergic effects can help.

Off‑label use should be documented with informed consent and coordinated between mental‑health teams, GPs and community pharmacists for monitoring.

• TGA‑Approved Indication: Obsessive–Compulsive Disorder (OCD).
• Common Off‑Label Uses: Severe depression, refractory panic disorder, augmentation in treatment‑resistant OCD or depression.

Composition And Brand Landscape In Australia

Patients often ask whether Anafranil is the same as clomipramine — it is, Anafranil being the most recognised brand name internationally.

The INN is clomipramine and Anafranil is the most widely recognised brand internationally and on Australian shelves.

Available oral strengths commonly include 10 mg (varies by supplier), 25 mg, 50 mg and 75 mg in capsule or tablet form.

ATC Classification: N06AA04 — tricyclic antidepressant with prominent serotonergic properties.

Contraindications And Special Precautions

People worry about safety in older relatives, pregnancy and in Indigenous communities with high comorbidity — careful screening is essential.

Absolute contraindications include recent myocardial infarction, hypersensitivity to clomipramine or other tricyclics, concurrent MAO inhibitor use and severe liver disease.

Elderly Australians have heightened anticholinergic vulnerability and increased risk of cardiac arrhythmia, so start at the lowest dose and titrate slowly while monitoring ECG and orthostatic signs.

Pregnancy and breastfeeding data are limited; clinicians must weigh maternal benefit against neonatal anticholinergic effects and potential withdrawal and involve obstetric services in decision making.

Indigenous and remote communities often have higher rates of cardiac disease, hepatic disease and polypharmacy, which increases risk and requires culturally appropriate counselling and thorough pre‑treatment screening.

Relative contraindications requiring caution include seizure history, urinary retention or prostatic hypertrophy, closed‑angle glaucoma and uncontrolled hyperthyroidism.

Daily‑life restrictions: advise patients to avoid driving or operating heavy machinery until they know how the medicine affects them because drowsiness and dizziness are common.

• Pre‑Treatment Checklist: cardiac history, current medicines (QT risk), seizure history, liver function, pregnancy planning and cultural supports for monitoring.

Dosage Guidelines And Practical Titration

One frequent question is “How quickly will Anafranil be increased?” — the answer is slowly and with monitoring.

Typical adult OCD initiation uses 25 mg at night, increasing by around 25 mg every few days to weeks as tolerated.

Typical maintenance for OCD ranges 100–250 mg/day in divided doses, with a maximum of 250 mg/day.

For depression and some off‑label uses doses commonly stay under 150 mg/day unless under specialist direction.

Paediatric OCD often starts at 25 mg/day with specialist titration up to approximately 3 mg/kg/day (max about 200 mg/day in adolescents), following paediatric guidance.

In elderly patients and those with cardiac risk, slower titration over several weeks and smaller stepwise increases are the norm, with ECG monitoring recommended if escalating beyond about 100 mg/day.

There are no formal hepatic or renal dose adjustments specified; clinical practice is to reduce dose and monitor closely in impairment.

Missed dose instruction: take when remembered unless near the next dose and do not double doses.

Interactions Overview

Patients frequently hand over long medication lists and ask which drugs clash with clomipramine — many do, so a careful review is essential.

Never combine clomipramine with MAO inhibitors because of the risk of serotonin syndrome and other life‑threatening reactions.

Concomitant use with other QT‑prolonging medications such as some antipsychotics and antiarrhythmics increases arrhythmia risk and requires a medicines review and ECG monitoring.

Potent CYP inhibitors, for example fluvoxamine and some systemic antifungals, can raise clomipramine levels and increase adverse effects; enzyme inducers may lower effectiveness.

Additive anticholinergic effects occur with first‑generation antihistamines, certain antipsychotics and urinary antispasmodics, raising confusion, dry mouth and constipation risk.

Alcohol increases sedation and may raise seizure risk; advise minimising or avoiding alcohol while taking clomipramine, particularly for patients in rural areas where patterns of alcohol use differ.

Caffeine has no direct major pharmacokinetic interaction but can worsen anxiety and insomnia while you are adjusting therapy.

Cultural Perceptions, Patient Habits And Access Patterns In Australia

Many people wonder whether anaferanil (Anafranil) is easy to access and how cultural differences affect uptake — the picture varies across cities and communities.

Urban patients commonly follow first‑line SSRI pathways via private psychiatrists or GPs, while rural and remote communities rely more on local GPs, pharmacists and telehealth outreach services.

Price sensitivity and PBS reliance influence patient choices, with many asking about subsidy and generic options at major chains such as Chemist Warehouse, Priceline and TerryWhite Chemmart.

Stigma around mental health still affects help‑seeking in some groups, while trust in the local pharmacist remains high, making pharmacists important for counselling and adherence support.

Indigenous health contexts require culturally safe communication and involvement of Aboriginal health workers and community services to support treatment and monitoring.

• Access Barriers: specialist wait times, rural supply delays, cost concerns and cultural barriers.
• Solutions: telehealth e‑scripts, community nursing support and trusted pharmacist counselling.

In our online pharmacy, anafranil is available without a prescription, with discreet delivery to Australia in 5‑14 days.

Availability And Pricing Patterns

Patients often ask whether anaferanil is cheaper through PBS or online; the difference can be significant depending on PBS eligibility.

Anafranil and generic clomipramine are available through community pharmacies (for example Chemist Warehouse, Priceline, TerryWhite Chemmart), hospital pharmacies and online suppliers with a valid prescription.

PBS listing determines subsidy eligibility and patient co‑payment, and when subsidised the out‑of‑pocket cost is substantially lower than private prescriptions.

Private prescriptions and non‑PBS brands cost more, so many patients request generic switches to reduce expense.

Rural supply can be variable and certain strengths or brands may require ordering with lead times; online pharmacies and mail delivery help bridge continuity for remote patients.

Comparable Medicines And Clinical Preference Checklist

Clinicians weighing options ask whether to try another SSRI or switch to clomipramine — the clinical context guides the choice.

First‑line treatments for OCD are SSRIs such as sertraline, fluoxetine and paroxetine, while clomipramine, a tricyclic antidepressant, is often reserved for second‑line use or as augmentation where SSRIs are insufficient.

Imipramine is a related TCA with less selective serotonergic action and is less commonly used for OCD.

Pros of clomipramine include a strong serotonergic effect that helps many refractory OCD patients where SSRIs fail.

Cons include higher anticholinergic burden, greater cardiovascular risk, sedation and more complex monitoring requirements compared with SSRIs.

• Preference Checklist For Clinicians: confirm prior adequate SSRI trials and doses, obtain baseline ECG, review seizure history and polypharmacy (QT‑risk drugs), discuss pregnancy plans, confirm ability to attend monitoring and check PBS subsidy status.

Frequently Asked Questions For Australian Patients

Q: Is Anafranil covered by PBS?

A: Coverage depends on indication and concession status; ask your GP or pharmacist to check PBS eligibility and cheaper generic options.

Q: Will it make me sleepy or cause weight gain?

A: Sedation, weight change and dry mouth are common side effects; taking the dose at bedtime and lifestyle measures may help.

Q: What monitoring is needed?

A: Baseline ECG if cardiac risk is present, regular blood‑pressure and heart‑rate checks, seizure‑history review and scheduled follow‑up for side effects; pharmacists often coordinate this monitoring.

Q: Can I drink alcohol or stop it suddenly?

A: Avoid alcohol due to added sedation and seizure risk; do not stop clomipramine abruptly — taper under medical supervision.

Key Safety Flags: QT prolongation risk, lowered seizure threshold, anticholinergic effects (dry mouth, constipation), and orthostatic hypotension.

Practical Counselling And Guidelines For Proper Use

Patients often come to the pharmacy wanting a simple checklist — here’s what to cover during counselling.

Confirm the indication and PBS eligibility and ensure a current, complete medication list is reviewed via My Health Record or the patient’s list.

Explain the dosing plan: start low, usually 25 mg at night, and titrate slowly; symptom improvement for OCD may take 4–12 weeks.

Discuss common side effects such as dry mouth, constipation, drowsiness and orthostatic dizziness and give practical tips like taking the tablet at night and staying hydrated.

Advise baseline ECG when there is cardiac history or when escalating above about 100 mg/day and schedule blood‑pressure and side‑effect reviews within 1–2 weeks of dose changes.

For remote or Indigenous patients arrange telehealth follow‑ups, community nurse checks and engagement with Aboriginal health services for culturally appropriate support.

• Printable Counselling Checklist: indication, starting dose, expected timeline, major side effects, interactions to avoid, when to seek urgent care, and follow‑up schedule.

Document counselling in pharmacy records and provide a printed medicine information sheet for the patient to take home.

Delivery Across Australia